AMP Annual Meeting & Expo (Association for Molecular Pathology)

Join us at the AMP Annual Meeting & Expo 2024

November 19 - 23, 2024

Vancouver, British Columbia (Canada)

Booth #1225

Corporate Workshop

Wednesday, November 20^th

10:00 AM – 10:50 AM

Vancouver Convention Center, Level 2, Room 208 & 209

Title: The value of internalizing FDA- authorized tumor genomic profiling solutions for tissue and liquid biopsy

Description: Clinical NGS has advanced precision oncology, enabling physicians to identify actionable biomarkers in patients to aid in therapy selection. This workshop highlights the value of internalizing FDA-cleared tissue and an FDA authorized targeted liquid biopsy tumor profiling kitted solutions with best-in-class bioinformatics to help provide greater access to cancer patients worldwide. This workshop will also showcase our new FDA de novo authorized liquid biopsy kitted solution and examine the validation data included in the FDA submission. Lastly, there will be a panel discussion of active users who will discuss their point of view on the value of internalizing these solutions.

Featured Panelists

Innovation Spotlight Stage

Thursday, November 21^st

12:40 PM – 1:10 PM

Innovation Spotlight Stage #2

Title: Enabling access to genomic profiling through the FDA- authorized decentralized liquid biopsy solution, PGDx elio™ plasma focus Dx

Description: Liquid biopsy next-generation sequencing assays help guide treatment selection in cancer patients, particularly when tumor tissue is unavailable. Analytical validation an FDA authorized targeted 33-gene kitted assay, PGDx elio™ plasma focus Dx, has shown that detection of cancer-associated variants in ctDNA is highly specific, sensitive, reproducible and accurate. 

Learn more about Labcorp Oncology's FDA authorized kitted tissue and liquid profiling solutions

Poster presentations:

Labcorp subject matter experts will be participating in the following discussions during the meeting.
 

Wednesday, November 20

11:00 – 11:50 AM
Vancouver Convention Center, Level 2, Rooms 212 & 213
Dr. Heidi Ko will be part of a panel discussion about the challenges and practice gaps affecting the implementation of precision oncology in clinical practice from the lens of an oncologist hosted by Illumina and Bayer.
Title: A Panel Discussion on Challenges and Practice Gaps Affecting Implementation of Oncology Precision Medicine

12:00 – 12:50 PM
Vancouver Convention Center, Level 1, Rooms118
Dr. Jennifer Dickey will be part of a panel discussion with other market leaders in the field of liquid biopsy.  The panelists will talk through the challenges and opportunities to bring MRD to clinical practice and clinical trial management. This session will be hosted by Ultima Genetics
Title: Fireside Chat with Market Leaders in the Liquid Biopsy Field: Bringing MRD Testing to Clinical Practice with High-quality Large-scale Sequencing at Low Cost

4:00 – 4:50 PM
Vancouver Convention Center, Level 2, Rooms 208 & 209
Comprehensive Genomic Profiling (CGP) enables targeted therapy in oncology by identifying actionable mutations in solid tumors. Formalin-fixed paraffin-embedded (FFPE) tissues are challenging for high-quality nucleic acid extraction, crucial for sequencing. We present the Sonication STAR, an automated solution developed by Hamilton, Covaris, and Labcorp, enhancing FFPE sample processing for CGP. This method reduces 'quantity not sufficient' (QNS) samples, improves sequencing performance, and increases fully reported tumor profiles by 16%, offering cost savings, efficiency, and reduced re-extractions in CGP workflows.
Title: High Throughput Genomic Profiling of Solid Tumor FFPE Specimens with Fully Automated Extraction